NN9423 / Novo Nordisk - LARVOL DELTA

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. (PubMed, Expert Opin Emerg Drugs) - "There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes.Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54728518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706).Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of..."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Novo Nordisk A/S

New P1 trial • Biosimilar • Metabolic Disorders • Obesity

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Novo Nordisk A/S; Active, not recruiting ➔ Completed

Clinical • Trial completion

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: Novo Nordisk A/S; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed